Utilisation of prophylactic mastectomy in 10 European centers

被引:19
作者
Evans, DGR
Anderson, E
Lalloo, F
Vasen, H
Beckmann, M
Eccles, D
Hodgson, S
Moller, P
Chang-Claude, J
Morrison, P
Stoppa-Lyonnet, D
Steel, M
Haites, N
机构
[1] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England
[2] Fdn Detect Hereditary Tumours, Leiden, Netherlands
[3] Univ Dusseldorf, Frauenklin, D-4000 Dusseldorf, Germany
[4] Wessex Reg Genet Serv, Southampton, Hants, England
[5] Guys Hosp, Div Med & Mol Genet, London SE1 9RT, England
[6] Norwegian Radium Hosp, Unit Med Genet, Oslo, Norway
[7] Belfast City Hosp, Dept Med Genet, Belfast BT9 7AD, Antrim, North Ireland
[8] Inst Curie, Unite Genet Oncol, Paris, France
[9] Univ Aberdeen, Dept Med Genet, Aberdeen, Scotland
关键词
D O I
10.1155/1999/605917
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Increasingly women at high risk of breast cancer are opting for prophylactic surgery to reduce their risks. Data from 10 European centres that offer a risk counselling and screening service to women at risk show different approaches to the option of preventive surgery, although most centres adhere to a protocol including at least two risk counselling sessions and a psychological assessment. Thus far the combined centres have data on 174 women who have undergone prophylactic mastectomy with in excess of 400 women years of follow up. Operations were carried out on women with lifetime risks of 25-80%, with an average annual expected incidence rate of 1% per women. No breast cancers have occurred in this cohort. Long term follow up on an extended group of women will be necessary to truly address the risk of subsequent breast cancer and the psychological sequelae.
引用
收藏
页码:148 / 151
页数:4
相关论文
共 13 条
  • [1] CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
  • [2] 2-5
  • [3] Eeles R, 1996, BRIT MED J, V313, P572
  • [4] Eeles R, 1996, Clin Oncol (R Coll Radiol), V8, P222, DOI 10.1016/S0936-6555(05)80656-9
  • [5] Fictitious breast cancer family history
    Evans, DGR
    Kerr, B
    Cade, D
    Hoare, E
    Hopwood, P
    [J]. LANCET, 1996, 348 (9033) : 1034 - 1034
  • [6] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695
  • [7] FAILURE OF SUBCUTANEOUS MASTECTOMY TO PREVENT THE DEVELOPMENT OF BREAST-CANCER
    GOODNIGHT, JE
    QUAGLIANA, JM
    MORTON, DL
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1984, 26 (03) : 198 - 201
  • [8] Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
    Hartmann, LC
    Schaid, DJ
    Woods, JE
    Crotty, TP
    Myers, JL
    Arnold, PG
    Petty, PM
    Sellers, TA
    Johnson, JL
    McDonnell, SK
    Frost, MH
    Jenkins, RB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) : 77 - 84
  • [9] Lynch HT, 1997, CANCER-AM CANCER SOC, V79, P2219, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>3.0.CO
  • [10] 2-Y